An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) THerapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects With Advanced Parkinson's Disease - INSIGHTS Study
Phase of Trial: Phase III
Latest Information Update: 13 Apr 2017
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms INSIGHTS
- Sponsors AbbVie
- 06 Jan 2017 Planned End Date changed from 1 Nov 2017 to 1 Nov 2018.
- 06 Jan 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.
- 10 Nov 2016 This trial was discontinued in Germany, according to European Clinical Trials Database.